Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

155393

registered interest
date	11/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy Tests
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when the Independent Panel on Hormone Pregnancy Tests will be set up; and what time frame he has set for that inquiry.
tabling member constituency	Bolton South East
tabling member printed	Yasmin Qureshi
uin	214308
answer	answer is ministerial correction date of answer 21/11/2014 answer text <p>Membership of the Group is currently being convened and will be finalised in December 2014. The time frame for the inquiry has yet to be finalised but the Panel is expected to review the evidence in the early months of 2015.</p><p> </p><p> </p><p> </p><p>Members of the Expert Working Group on Hormone Pregnancy Tests will be expected to declare any interests (financial or non-financial) in the pharmaceutical industry or in any other area that could affect their impartiality. All members’ interests will be carefully considered in advance and assessed when deciding on the appropriate level of participation in discussions.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 214307 question first answered 21/11/2014 14:26:47 answering member 4020 label Biography information for George Freeman
tabling member	3924 label Biography information for Yasmin Qureshi

155394

registered interest
date	11/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy Tests
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent steps he has taken to ensure the impartiality and neutrality of members of the panel on hormone pregnancy tests.
tabling member constituency	Bolton South East
tabling member printed	Yasmin Qureshi
uin	214307
answer	answer is ministerial correction date of answer 21/11/2014 answer text <p>Membership of the Group is currently being convened and will be finalised in December 2014. The time frame for the inquiry has yet to be finalised but the Panel is expected to review the evidence in the early months of 2015.</p><p> </p><p> </p><p> </p><p>Members of the Expert Working Group on Hormone Pregnancy Tests will be expected to declare any interests (financial or non-financial) in the pharmaceutical industry or in any other area that could affect their impartiality. All members’ interests will be carefully considered in advance and assessed when deciding on the appropriate level of participation in discussions.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 214308 question first answered 21/11/2014 14:26:46 answering member 4020 label Biography information for George Freeman
tabling member	3924 label Biography information for Yasmin Qureshi

147552

registered interest
date	10/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Breast Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure that (a) NHS England continues to routinely assess the quality and safety of local breast cancer multi-disciplinary teams and network groups as part of the National Cancer Peer Review programme and (b) this information is made available to patients through the My Cancer Treatment website.
tabling member constituency	Bolton South East
tabling member printed	Yasmin Qureshi
uin	213933
answer	answer is ministerial correction date of answer 20/11/2014 answer text <p>NHS England is currently reviewing the National Cancer Peer Review Programme with a view to considering how its success might be extended into other new areas of specialised commissioning. Further details, including how the public can access information on the quality of clinical services, will be available following the completion of the review.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 20/11/2014 16:45:59 answering member 3918 label Biography information for Jane Ellison
tabling member	3924 label Biography information for Yasmin Qureshi

147553

registered interest
date	10/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure routine access to tamoxifen and raloxifene for the indication of chemoprevention in the UK.
tabling member constituency	Bolton South East
tabling member printed	Yasmin Qureshi
uin	213936
answer	answer is ministerial correction date of answer 19/11/2014 answer text <p>In June 2013 the National Institute for Health and Care Excellence (NICE) issued an updated clinical guideline on familial breast cancer which includes recommendations on the use of tamoxifen and raloxifene outside their licensed indications for the prevention of cancer in specific groups of women at high and moderate risk of breast cancer.</p><p> </p><p> </p><p> </p><p>NICE’s clinical guidelines represent best practice and we expect commissioners to take their recommendations into account when designing services and making commissioning decisions for their healthcare population.</p><p> </p><p><strong> </strong></p><p> </p><p>Information on the number of women treated with tamoxifen and raloxifene for the treatment or prevention of breast cancer is not collected centrally.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 213934 question first answered 19/11/2014 15:55:55 answering member 4020 label Biography information for George Freeman
tabling member	3924 label Biography information for Yasmin Qureshi

147554

registered interest
date	10/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what proportion of women who are eligible for tamoxifen and raloxifene are offered this treatment.
tabling member constituency	Bolton South East
tabling member printed	Yasmin Qureshi
uin	213934
answer	answer is ministerial correction date of answer 19/11/2014 answer text <p>In June 2013 the National Institute for Health and Care Excellence (NICE) issued an updated clinical guideline on familial breast cancer which includes recommendations on the use of tamoxifen and raloxifene outside their licensed indications for the prevention of cancer in specific groups of women at high and moderate risk of breast cancer.</p><p> </p><p> </p><p> </p><p>NICE’s clinical guidelines represent best practice and we expect commissioners to take their recommendations into account when designing services and making commissioning decisions for their healthcare population.</p><p> </p><p><strong> </strong></p><p> </p><p>Information on the number of women treated with tamoxifen and raloxifene for the treatment or prevention of breast cancer is not collected centrally.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 213936 question first answered 19/11/2014 15:55:55 answering member 4020 label Biography information for George Freeman
tabling member	3924 label Biography information for Yasmin Qureshi

147555

registered interest
date	10/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services: Eastleigh
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will provide funding to support the delivery of more healthcare services from the Moorgreen Hospital site in Eastleigh constituency.
tabling member constituency	Eastleigh
tabling member printed	Mr Michael Thornton
uin	213957
answer	answer is ministerial correction date of answer 19/11/2014 answer text <p>This is a matter for West Hampshire Clinical Commissioning Group (CCG).</p><p> </p><p> </p><p> </p><p>We are advised that ownership of Moorgreen Hospital has been transferred to NHS Property Services and it is working with commissioners to plan for the site’s future use in line with the CCG’s commissioning proposals.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 19/11/2014 15:14:51 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	4273 label Biography information for Mr Mike Thornton

147556

registered interest
date	10/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neuromuscular Disorders
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many cough assist machines clinical commissioning groups have funded for patients with muscular dystrophy and neuromuscular conditions in the last 12 months.
tabling member constituency	Blaydon
tabling member printed	Mr David Anderson
uin	213953
answer	answer is ministerial correction date of answer 19/11/2014 answer text <p>The Department does not hold figures on the number of cough assist machines clinical commissioning groups (CCGs) have funded for patients with muscular dystrophy and neuromuscular conditions in the last 12 months. Funding for cough assist machines is a matter for individual CCGs taking into account the individual circumstances of each patient.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 19/11/2014 15:16:47 answering member 1439 label Biography information for Norman Lamb
tabling member	1486 label Biography information for Mr David Anderson

147557

registered interest
date	10/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Procurement
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many contracts signed by his Department with suppliers of services or consultants include a clause providing that if the contract is abrogated by the Government, the provider or consultant will be compensated for lost income since 2010.
tabling member constituency	Great Grimsby
tabling member printed	Austin Mitchell
uin	214009
answer	answer is ministerial correction date of answer 19/11/2014 answer text <p>Information for all contracts is not held centrally and to provide a complete answer would result in disproportionate cost.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 19/11/2014 15:31:32 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	372 label Biography information for Austin Mitchell

147558

registered interest
date	10/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to develop and support the cancer screening programme.
tabling member constituency	Mid Derbyshire
tabling member printed	Pauline Latham
uin	214020
answer	answer is ministerial correction date of answer 18/11/2014 answer text <p>The NHS Cancer Screening Programmes screen millions of people each year in order to detect cancer or abnormalities which could develop into cancer if left undetected and untreated. They are supported by a national co-ordinating team and regional quality assurance teams in Public Health England (PHE).</p><p> </p><p> </p><p> </p><p>On the specific programmes, NHS England and PHE are working together to set up screening centres for Bowel Scope Screening (BSS) for 55 year-olds as an addition to the current NHS Bowel Cancer Screening Programme. Our commitment is to have BSS rolled out to 60% of screening centres in England by the end of March 2015, and to all screening centres in England by the end of 2016. In addition, as part of the original programme, PHE are piloting a new form of home testing kit (faecal immunochemical testing - FIT) which is easier to use and potentially more accurate than the current faecal occult blood (FOB) test used in the programme.</p><p> </p><p> </p><p> </p><p>The NHS Breast Cancer Screening Programme has developed considerably with the use of digital mammography in screening clinics and the extensions to the age range for screening women, including the current randomised controlled trial screening 47-49 and 71-73 year-old women. Around 97.1% of women who have had invasive breast cancer detected by screening are alive five years later and over three quarters of the women whose cancer is detected by the programme do not need chemotherapy.</p><p> </p><p> </p><p> </p><p>The NHS Cervical Screening Programme is currently piloting the use of human papillomavirus (HPV) testing as the primary screen for cervical disease in order to achieve better, more personalised outcomes for women. Through early detection and treatment the NHS Cervical Screening Programme can prevent around 75% of cervical cancers developing; where an early cancer is found, women with cervical cancer diagnosed by screening have a better chance of being cured than those who present with symptoms.</p><p> </p><p> </p><p> </p><p>All NHS screening programmes are based on National Screening Committee recommendations using the best evidence available.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 18/11/2014 14:08:12 answering member 3918 label Biography information for Jane Ellison
tabling member	4025 label Biography information for Mrs Pauline Latham

147559

registered interest
date	10/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will take steps to ensure that clinically-proven, cost-effective drugs are made routinely available to all when they are shown to be of use in a new indication but are off-patent.
tabling member constituency	Bolton South East
tabling member printed	Yasmin Qureshi
uin	214030
answer	answer is ministerial correction date of answer 19/11/2014 answer text <p>We support appropriate use of off-patent medicines in areas where the evidence suggests that they can deliver patient benefit. Doctors can already prescribe a drug outside its licensed indications where they judge it to be the most clinically appropriate treatment for an individual patient. Medicines are routinely prescribed legally, safely and appropriately outside their licensed indications to large numbers of National Health Service patients.</p><p> </p><p> </p><p> </p><p>We are in the process of setting up a round-table discussion with key stakeholders, NHS England and the National Institute for Health and Care Excellence to review the evidence and explore opportunities to work together to better support appropriate use of these medicines.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 19/11/2014 16:02:12 answering member 4020 label Biography information for George Freeman
tabling member	3924 label Biography information for Yasmin Qureshi